Prognosis in Patients with Non-Small Cell Lung Cancer Who Received Erlotinib Treatment and Subsequent Dose Reduction due to Skin Rash | Zendy

Naoki Takashima | Zendy; Toshikiro Kimura | Zendy; Naohiro Watanabe | Zendy; Takumi Umemura | Zendy; Shinya Katsuno | Zendy; Keiko Arakawa | Zendy; Masahiro Fukatsu | Zendy; Naoto Nakamura | Zendy; Osamu Nishiyama | Zendy; Kensuke Kataoka | Zendy; Yasuhiro Kondoh | Zendy; Hiroyuki Taniguchi | Zendy

Open Access

Prognosis in Patients with Non-Small Cell Lung Cancer Who Received Erlotinib Treatment and Subsequent Dose Reduction due to Skin Rash

Author(s) -

Naoki Takashima,

Toshikiro Kimura,

Naohiro Watanabe,

Takumi Umemura,

Shinya Katsuno,

Keiko Arakawa,

Masahiro Fukatsu,

Naoto Nakamura,

Osamu Nishiyama,

Kensuke Kataoka,

Yasuhiro Kondoh,

Hiroyuki Taniguchi

Publication year - 2012

Publication title -

onkologie

Language(s) - English

Resource type - Journals

eISSN - 1423-0240

pISSN - 0378-584X

DOI - 10.1159/000345039

Subject(s) - erlotinib , rash , medicine , erlotinib hydrochloride , lung cancer , epidermal growth factor receptor , adverse effect , gastroenterology , dermatology , oncology , cancer

Severe skin rash as toxicity of erlotinib has been reported in relation to better response and survival. However, some patients require dose reduction due to skin toxicities, and their prognosis remains uncertain. We retrospectively evaluated the clinical course of non-small cell lung cancer patients receiving erlotinib at a reduced dose because of skin rash.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research